Global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine Market Professional Survey Report 2019

Hepatitis B is a viral infection caused due to transmission of the virus through contact with the blood or other body fluids of an infected person. It is considered as a serious occupational hazard for healthcare professionals, which affects the liver, causing acute and chronic diseases. Hence, Chinese hamster ovary cell (CHO) hepatitis B vaccine is considered to be the safe and effective method to prevent the hepatitis B infection. The major factor that fuels the growth of the market are increase in prevalence of hepatitis B infection worldwide. For example, approximately 887,000 deaths due to hepatitis B infection were recorded in 2015 across the globe. However, inherent disadvantages of using recombinant Chinese hamster ovary cell (CHO) to design hepatitis B vaccines restrains the growth of the market. Conversely, increase in government focus to promote (CHO) hepatitis B vaccination for adults and extensive research carried out for the same are expected to offer lucrative opportunities for the market.

The global Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Merck & Co., Inc.
GlaxoSmithKline Plc
Pfizer Inc.
Sanofi Pasteur
CSL Limited
Emergent Biosolutions
Serum Institute of India
Johnson & Johnson

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Pediatric Hepatitis B (CHO) Vaccine
Adult Hepatitis B (CHO) Vaccine

Segment by Application
Hospitals
Clinics